Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Ovid Therapeutics Inc. (OVID) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.25 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 1.25M shares, a 99.75% increase year-over-year.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 1.20M shares, a 511.64% increase year-over-year.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 80.42K shares, a 95.76% decline year-over-year.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 918.31K shares, a 40.52% decline year-over-year.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 1.82M shares, a 57.02% decline from fiscal 2024.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 4.23M shares, a 481.45% increase from fiscal 2023.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 728.35K shares, a 69.21% decline from fiscal 2022.
- Ovid Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 2.37M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.25M shares 10-Q · filed 2026-08-13 | 2.45M shares derived: sum of 2 quarters · filed 2026-08-13 | 2.53M shares derived: sum of 3 quarters · filed 2026-08-13 | 3.45M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 1.20M shares 10-Q · filed 2026-05-12 | 1.29M shares derived: sum of 2 quarters · filed 2026-05-12 | 2.20M shares derived: sum of 3 quarters · filed 2026-05-12 | 2.83M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 80.42K shares derived: 10-K 12 month − 3 quarters · filed 2026-03-18 | 998.73K shares derived: sum of 2 quarters · filed 2026-03-18 | 1.62M shares derived: sum of 3 quarters · filed 2026-03-18 | 1.82M shares 10-K · filed 2026-03-18 |
| 2025-09-30 | 918.31K shares 10-Q · filed 2025-11-12 | 1.54M shares derived: sum of 2 quarters · filed 2025-11-12 | 1.74M shares derived: sum of 3 quarters · filed 2025-11-12 | 3.63M shares derived: sum of 4 quarters · filed 2026-03-18 |
| 2025-06-30 | 624.55K shares 10-Q · filed 2025-08-13 | 821.55K shares derived: sum of 2 quarters · filed 2025-08-13 | 2.72M shares derived: sum of 3 quarters · filed 2026-03-18 | 4.26M shares derived: sum of 4 quarters · filed 2026-03-18 |
| 2025-03-31 | 197.00K shares 10-Q · filed 2025-05-13 | 2.09M shares derived: sum of 2 quarters · filed 2026-03-18 | 3.64M shares derived: sum of 3 quarters · filed 2026-03-18 | 4.07M shares derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-12-31 | 1.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | 3.44M shares derived: sum of 2 quarters · filed 2026-03-18 | 3.87M shares derived: sum of 3 quarters · filed 2026-03-18 | 4.23M shares 10-K · filed 2026-03-18 |
| 2024-09-30 | 1.54M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.98M shares derived: sum of 2 quarters · filed 2024-11-12 | 2.34M shares 10-Q · filed 2024-11-12 | 2.40M shares derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | 433.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 796.36K shares 10-Q · filed 2024-08-13 | 858.75K shares derived: sum of 3 quarters · filed 2025-03-11 | 1.10M shares derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | 363.21K shares 10-Q · filed 2024-05-14 | 425.60K shares derived: sum of 2 quarters · filed 2025-03-11 | 669.73K shares derived: sum of 3 quarters · filed 2025-03-11 | 897.62K shares derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | 62.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 306.52K shares derived: sum of 2 quarters · filed 2025-03-11 | 534.41K shares derived: sum of 3 quarters · filed 2025-03-11 | 728.35K shares 10-K · filed 2025-03-11 |
| 2023-09-30 | 244.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 472.02K shares derived: sum of 2 quarters · filed 2023-11-03 | 665.96K shares 10-Q · filed 2023-11-03 | 737.98K shares derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-06-30 | 227.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | 421.82K shares 10-Q · filed 2023-08-04 | 493.85K shares derived: sum of 3 quarters · filed 2024-03-08 | 1.18M shares derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-03-31 | 193.94K shares 10-Q · filed 2023-05-05 | 265.96K shares derived: sum of 2 quarters · filed 2024-03-08 | 953.88K shares derived: sum of 3 quarters · filed 2024-03-08 | 2.13M shares derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-12-31 | 72.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 759.94K shares derived: sum of 2 quarters · filed 2024-03-08 | 1.93M shares derived: sum of 3 quarters · filed 2024-03-08 | 2.37M shares 10-K · filed 2024-03-08 |
| 2022-09-30 | 687.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 1.86M shares derived: sum of 2 quarters · filed 2022-11-08 | 2.29M shares 10-Q · filed 2022-11-08 | |
| 2022-06-30 | 1.17M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 1.61M shares 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | 434.10K shares 10-Q · filed 2022-05-10 | |||
| 2021-09-30 | 637.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 997.98K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.03M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 360.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 388.61K shares 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | 28.44K shares 10-Q · filed 2021-05-13 | |||
| 2020-09-30 | 125.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | 304.58K shares derived: sum of 2 quarters · filed 2020-11-13 | 360.61K shares 10-Q · filed 2020-11-13 | |
| 2020-06-30 | 178.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 234.80K shares 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | 56.03K shares 10-Q · filed 2020-05-07 | |||
| 2019-09-30 | 128.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | 540.02K shares derived: sum of 2 quarters · filed 2019-11-08 | 791.74K shares 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 411.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 663.15K shares 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | 251.72K shares 10-Q · filed 2019-05-07 | |||
| 2018-09-30 | 401.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 437.72K shares 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | 35.98K shares 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |